Nathan Bryson

Bionisis SA distributes spearation instruments. The firm markets sorbent beds and accessories based on its patented OPLC technology(Optimum Performance Laminar ChromatographyTM). The firm provides solutions to chemists in the fields of organic synthesis, natural products, medicinal chemistry, drug discovery, lead optimization, toxicology, drug metabolism, forensic science, analytical development, chemical process R&D and manufacturing & quality control. The company was founded in 1999 and is headquartered in Le Plessis-Robinson, France

Cynapsus Therapeutics, Inc. operated as a pharmaceutical company, which developed an improved dosing formulation of an approved drug used to treat the symptoms of Parkinson's disease. The company was founded by Andrew Williams and David Hill on January 16, 2004 and was headquartered in Toronto, Canada.

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

Field Trip Health Ltd. engages in development and delivery of technology-enabled psychedelic therapies. It offers psychedelic-enhanced and psychedelic-integration psychotherapy. The firm is developing patient-centric and evidence-based psychedelic approaches to behavioral and mental health. The company was founded by Joseph del Moral, Ronan Levy, Hannan Fleiman, Syed Mujeeb Jafferi, and Ryan Yermus on September 30, 2008 and is headquartered in Toronto, Canada.

Matregen Corp. engaged in the development and commercialization of novel Drug Delivery Systems. Its SpinFX technology is a technique used to produce novel structures such as porous tubes, composites, and coatings. The company was founded by Dr. Molly S. Shoichet and Dr. Paul D. Dalton in 2002 and is headquartered in Toronto, Canada.

Flamel Technologies SA engages in the research, development and commercialization of pharmaceutical products. Its portfolio includes Bloxiverz, Vazculep, Micropump, LiquiTime, Trigger Lock and Medusa. The company was founded by Gérard Soula in August 1990 and is headquartered in Vénissieux, France.